Quote:

---

tumor cells needs to have significant expression of CCR5 for inclusion in the trial.

---

I believe this was the case when RP ran the tnbc trial. (or did not run the trial.)

Quote:

---

The discussion indicates that CCR5 inhibition (leronlimab), by interrupting macrophage depolarization, may likely have anti tumor properties, even in the absence of high tumor CCR5 expression.

---

Bruce Patterson (BP) was very gracious with his time helping a friend of mine fighting cancer a year ago. The IHC test performed by Dr. Rui Hallgeir showed no or minimal CCR5 expression on the cancer. BP indicated that Leronlimab may still help if the surrounding macrophages express CCR5 and requested to personally review the stained slides to check for it.